Three things to know:
1. The orthopedic diagnostics company will use the funds to expand its worldwide commercialization efforts for its mi-eye 2 and mi-ultra. Trice will also use the funds to accelerate the development of its minimally invasive product portfolio.
2. Charter Capital Partners and the Municipal Employees’ Retirement System of Michigan led the round.
3. Trice’s mi-eye is a fully disposable arthroscopy camera. The company recently introduced the mi-ultra, a handheld ultrasound transducer that works on a single-portable platform.
More articles on devices:
Si-Bone reports 2018 sales to range between $55.2M to $55.4M: 5 financial details
Joint reconstruction devices market to exceed $21.5B by 2024: 5 details
SpineSource acquires assets to 2 spinal implant systems: 4 key notes
